Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.
Pharma & Biotech